Similar articles

• [Clinical experiences with pepleomycin (NK 631) (author's transl)].

  Kusakari J, Sato Y, Saijo S, Tomioka S, Kawamoto K. Kusakari J, et al. Jpn J Antibiot. 1978 Nov;31(11):659-63. Jpn J Antibiot. 1978. PMID: 83402 Japanese. No abstract available.
• [Clinical application of NK 631 to head-and-neck cancers (author's transl)].

  Ogawa Y, Omata T, Imaizumi H, Shiga H, Ouchi J. Ogawa Y, et al. Jpn J Antibiot. 1979 Jan;32(1):115-20. Jpn J Antibiot. 1979. PMID: 84881 Japanese.
• [Clinical effects of NK 631 in malignant tumors of the oral cavity (author's transl)].

  Kawahira K, Dohhara Y, Sugihara K, Yamada K, Fujinami Y, Saku T, Yamashita S. Kawahira K, et al. Jpn J Antibiot. 1979 Jan;32(1):138-48. Jpn J Antibiot. 1979. PMID: 84884 Japanese. No abstract available.
• Chemoprevention in the management of oral cancer: EUROSCAN and other studies.

  de Vries N, van Zandwijk N, Pastorino U. de Vries N, et al. Eur J Cancer B Oral Oncol. 1992 Oct;28B(2):153-7. doi: 10.1016/0964-1955(92)90045-3. Eur J Cancer B Oral Oncol. 1992. PMID: 1306732 Review. No abstract available.
• [Pathology of head and neck cancers].

  Ochiai A. Ochiai A. Nihon Jibiinkoka Gakkai Kaiho. 2010 Jun;113(6):535-41. doi: 10.3950/jibiinkoka.113.535. Nihon Jibiinkoka Gakkai Kaiho. 2010. PMID: 20726174 Review. Japanese. No abstract available.